GSK's TYKERB(R) Receives Accelerated Approval For First-Line Combination Treatment Of
 

GlaxoSmithKline (NYSE: GSK) announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for a new combination regimen using TYKERB® (lapatinib) as a first-line, all-oral treatment for women with metastatic breast cancer...

More...